

PUBLICACIONES EN REVISTAS INDEXADAS EN EL 2022

Durante el año 2022, se han realizado 47 publicaciones por miembros del servicio (13 como primer o último autor y 6 publicaciones con tres o más autores del servicio), con un **factor de impacto acumulado de 453 (FI medio 8.88)**. Han firmado como autores un total de **15 miembros del servicio (33%)**.

A predictive model of immune recovery for DTG + 3TC and DTG + RPV used as switching strategies in HIV+ patients.

Troya J, Pedrero-Tomé R, Dueñas C, Buzón L. *J Antimicrob Chemother.* 2022 Nov 28;77(12):3519-3523. doi: 10.1093/jac/dkac354.

IF: 5.2 Q2

Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs.

Valencia J, **Troya J**, Lazarus JV, Cuevas G, Alvaro-Meca A, Torres-Machado J, Escobar I, Cañamares I, Ryan P. *AIDS Care.* 2022 Oct;34(10):1297-1304. doi: 10.1080/09540121.2021.1967853. Epub 2021 Sep 6.

IF: 4.9 Q2.

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.

Perez Stachowski J, Rial Crestelo D, Moreno Zamora A, Cabello N, Ryan P, Espinosa Aguilera N, Bisbal O, Vivancos Gallego MJ, Nuñez MJ, **Troya J**, Dominguez M, Sierra JO. *J Clin Med.* 2022 Aug 25;11(17):4994. doi: 10.3390/jcm11174994.

iF: 3.9 Q2

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPLEX retrospective study.

Troya J, Dueñas C, Irazola I, de Los Santos I, de la Fuente S, Gil D, Hernández C, Galindo MJ, Gómez J, Delgado E, Moreno-García E, Pousada G, Aldámiz T, Iribarren JA, Guerra JM, Morán MÁ, Galera C, De La Fuente J, Peláez A, Cervero M, Garcinuño M, Montero M, Ceballos F, Buzón L; on behalf of the DORIPLEX Study Group.

Medicine (Baltimore). 2022 Jun 17;101(24):e29252. doi:
10.1097/MD.00000000000029252.

IF: 1.6 Q3.

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.

Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A, Le Voyer T, Bizien L, Zamecnik C, Philippot Q, Rosain J, Catherinot E, Willmore A, Mitchell AM, Bair R, Garçon P, Kenney H, Fekkar A, Salagianni M, Poulakou G, Siouti E, Sahanic S, Tancevski I, Weiss G, Nagl L, Manry J, Duvlis S, Arroyo-Sánchez D, Paz Artal E, Rubio L, Perani C, Bezzi M, Sottini A, Quaresima V, Roussel L, Vinh DC, Reyes LF, Garzaro M, Hatipoglu N, Boutboul D, Tandjaoui-Lambiotte Y, Borghesi A, Aliberti A, Cassaniti I, Venet F, Monneret G, Halwani R, Sharif-Askari NS, Danielson J, Burrel S, Morbieu C, Stepanovskyy Y, Bondarenko A, Volokha A, Boyarchuk O, Gagro A, Neuville M, Neven B, Keles S, Hernu R, Bal A, Novelli A, Novelli G, Saker K, Ailioaie O, Antolí A, Jeziorski E, Rocamora-Blanch G, Teixeira C, Delaunay C, Lhuillier M, Le Turnier P, Zhang Y, Mahevas M, Pan-Hammarström Q, Abolhassani H, Bompoil T, Dorgham K; COVID HGE consortium †; French COVID study group †; COMET consortium †; Gorochov G, Laouenan C, Rodríguez-Gallego C, Ng LFP, Renia L, Pujol A, Belot A, Raffi F, Allende LM, Martínez-Picado J, Ozcelik T, Keles S, Imberti L, Notarangelo LD, **Troya J**, Solanich X, Zhang SY, Puel A, Wilson MR,...See abstract for full author list → *Sci Immunol.* 2022 Jun 14:eabp8966. doi: 10.1126/sciimmunol.abp8966. Online ahead of print.

IF: 24.8 Q1.

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekanu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, **Troya J**, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Mégarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau...See abstract for full author list →

Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119. doi: 10.1073/pnas.2200413119. Epub

IF: 10.7. Q1.

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality.

Troya J, Bastard P, Casanova JL, Abel L, Pujol A.

J Clin Immunol. 2022 May;42(4):738-741. doi: 10.1007/s10875-022-01241-5. Epub 2022 Mar 3.

IF: 9.1 Q1

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).

Podzamczar D, Micán R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masiá M, Gómez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro Á, Bernal E, Vinuesa D, Knobel H, **Troya J**, Macías J, Montero M, Sanz J, Navarro-Alcaraz A, Caicedo A, Fernández G, Martínez E, Moreno S. Open Forum Infect Dis. 2021 Nov 25;9(3):ofab595. doi: 10.1093/ofid/ofab595. eCollection 2022 Mar. PMID: 35237700 **Free PMC article.**

IF: 4.2 Q3.

HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization.

Valle-Millares D, Brochado-Kith Ó, Gómez-Sanz A, Martín-Carbonero L, Ryan P, De Los Santos I, Castro JM, **Troya J**, Mayoral-Muñoz M, Cuevas G, Martínez-Román P, Sanz-Sanz J, Muñoz-Muñoz M, Jiménez-Sousa MÁ, Resino S, Briz V, Fernández-Rodríguez A; multidisciplinary Group of viral coinfection HIV/Hepatitis (COVIHEP). Biomed Pharmacother. 2022 Jan;145:112405. doi: 10.1016/j.biopha.2021.112405. Epub 2021 Nov 12.

IF: 7.5 Q1

Pregnancy Outcomes Among Perinatally HIV-Infected Women in Spain.

Nogueira López J, Prieto-Tato L, Escosa-García L, Bernardino JI, Muñoz E, Díez C, Carrasco I, **Ryan P**, Guillén-Martín S, Ramos-Amador JT, Navarro ML, Holguín A, Sainz

T; CoRISpe Group. J Acquir Immune Defic Syndr. 2022 Dec 1;91(4):373-380. doi: 10.1097/QAI.0000000000003070. Epub 2022 Oct 10.

IF: 3.6 Q1

Plasma miRNA profile at COVID-19 onset predicts severity status and mortality.

Fernández-Pato A, Virseda-Berdices A, Resino S, **Ryan P**, Martínez-González O, Pérez-García F, Martín-Vicente M, Valle-Millares D, Brochado-Kith O, Blancas R, Martínez A, Ceballos FC, Bartolome-Sánchez S, Vidal-Alcántara EJ, Alonso D, Blanca-López N, Ramírez Martínez-Acitores I, Martín-Pedraza L, Jiménez-Sousa MÁ, Fernández-Rodríguez A. Emerg Microbes Infect. 2022 Dec;11(1):676-688. doi: 10.1080/22221751.2022.2038021.

IF: 13.2 Q1

Neighborhood environmental factors linked to hospitalizations of older people for viral lower respiratory tract infections in Spain: a case-crossover study.

Álvaro-Meca A, Sepúlveda-Crespo D, Resino R, **Ryan P**, Martínez I, Resino S. Environ Health. 2022 Nov 8;21(1):107. doi: 10.1186/s12940-022-00928-x.

iF: 6 Q1

Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation.

Ceballos FC, Virseda-Berdices A, Resino S, **Ryan P**, Martínez-González O, Pérez-García F, Martín-Vicente M, Brochado-Kith O, Blancas R, Bartolome-Sánchez S, Vidal-Alcántara EJ, Albóniga-Díez OE, Cuadros-González J, Blanca-López N, Martínez I, Martínez-Acitores IR, Barbas C, Fernández-Rodríguez A, Jiménez-Sousa MÁ. Front Immunol. 2022 Jun 30;13:925558. doi: 10.3389/fimmu.2022.925558. eCollection 2022.

iF 7.3. Q1

Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance.

Martínez-Román P, Crespo-Bermejo C, Valle-Millares D, Lara-Aguilar V, Arca-Lafuente S, Martín-Carbonero L, **Ryan P**, de Los Santos I, López-Huertas MR, Palladino C, Muñoz-Muñoz M, Fernández-Rodríguez A, Coiras M, Briz V, On Behalf Of The Covihep Network. J Clin Med. 2022 Jun 21;11(13):3579. doi: 10.3390/jcm11133579.

IF: 3.9 Q2

Misdiagnosis rate among negative COVID-19 patients in real-life with Panbio COVID-19 antigen rapid test during 2021.

Ryan P, Pérez-García F, Torres-Macho J, Bibiano C, Ignacio Lazo J, Castaño-Ochoa G, Vidal-Alcántara EJ, Muñoz-Gómez MJ, Martínez I, Resino S.J *Infect.* 2022 May;84(5):e42-e44. doi: 10.1016/j.jinf.2022.03.013. Epub 2022 Mar 16.

IF. 28.2 Q1

Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: The FUNCFRIL cohort study (GeSIDA 9817).

Brañas F, Galindo MJ, Torralba M, Antela A, Vergas J, Ramírez M, **Ryan P**, Dronda F, Busca C, Machuca I, Bustinduy MJ, Cabello A, Sánchez-Conde M; FUNCFRIL study group. *PLoS One.* 2022 Mar 30;17(3):e0266191. doi: 10.1371/journal.pone.0266191. eCollection 2022.

IF: 3.7 Q2

Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19.

Martín-Vicente M, Berenguer J, Muñoz-Gómez MJ, Díez C, Micán R, Pérez-Elías MJ, García-Fraile LJ, Peraire J, Suárez-García I, Jiménez-Sousa MÁ, Fernández-Rodríguez A, Vázquez M, **Ryan P**, González-García J, Jarrín I, Mas V, Martínez I, Resino S.J *Infect.* 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.002. Epub 2021 Nov 6.

IF. 28.2 Q1

A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid.

Lazarus JV, Villota-Rivas M, Fernández I, Gea F, **Ryan P**, López SA, Guy D, Calleja JL, García-Samaniego J. *Commun Med (Lond).* 2022 Feb 24;2:20. doi: 10.1038/s43856-022-00077-9. eCollection 2022.

Impact of early interferon- β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort.

Salto-Alejandre S, Palacios-Baena ZR, Arribas JR, Berenguer J, Carratalà J, Jarrín I, **Ryan P**, Miguel-Montero M, Rodríguez-Baño J, Pachón J; COVID-19@Spain Study Group. *Biomed Pharmacother.* 2022 Feb;146:112572. doi: 10.1016/j.biopha.2021.112572. Epub 2021 Dec 22. PMID: 34954640 **Free PMC article.**

IF: 7.5 Q1

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, **Ryan P**, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. *N Engl J Med.* 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.

IF: 158.5 Q1

Characterisation of the coexistence between sarcoidosis and Sjögren's syndrome. Analysis of 43 patients.

Flores-Chavez A, Ng WF, Alunno A, Inanc N, Feijoo-Massó C, Seror R, Hernandez-Molina G, Devauchelle-Pensec V, Hofauer B, Pasoto SG, Robles A, **Akasbi M**, López-Dupla M, Retamozo S, Bandeira M, Romão VC, Carubbi F, Loaiza-Cabello D, García-Morillo JS, Benegas M, Sánchez M, Muxí Á, Fuster D, Sellarés J, Mariette X, Ramos-Casals M, Brito-Zéron P; Sarco-GEAS-SEMI and Sjogren Big Data Consortium. *Clin Exp Rheumatol.* 2022 Dec;40(12):2329-2337. doi: 10.55563/clinexprheumatol/pg964c. Epub 2022 Dec 20.

IF: 3.7 Q3

Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.

Inanc N, Kostov B, Priori R, Flores-Chavez A, Carubbi F, Szántó A, Valim V, Bootsma H, Praprotnik S, Fernandes Moça Trevisani V, Hernández-Molina G, Hofauer B, Pasoto SG, López-Dupla M, Bartoloni E, Rischmueller M, Devauchelle-Pensec V, Abacar K, Giardina F, Alunno A, Fanny Horváth I, de Wolff L, Caldas L, Retamozo S, Ramos-Casals M, Brito-Zerón P; Sjögren Big Data Consortium. *Clin Exp Rheumatol.* 2022 Dec;40(12):2290-2297. doi: 10.55563/clinexprheumatol/dt6klo. Epub 2022 Nov 17.

IF 3.7 Q3

Practical diagnostic tips for the Sjögren Clinic: pearls, myths and mistakes.

Brito-Zerón P, Retamozo S, Flores-Chávez A, **Akasbi M**, Sisó-Almirall A, Ramos-Casals M; Sjögren Syndrome Study Group, GEAS-SEMI. *Clin Exp Rheumatol.* 2022 Dec;40(12):2413-2427. doi: 10.55563/clinexprheumatol/3bvq48. Epub 2022 Oct 5.

IF: 3.7 Q3

Prevalence of thrombosis in patients with cancer and SARS-CoV-2 infection.

Obispo B, Rogado J, **Muñoz-Rivas N**, Pangua C, Serrano G, Lara MA; Infanta Leonor Thrombosis Research Group. *Med Clin (Engl Ed)*. 2022 Sep 9;159(5):234-237. doi: 10.1016/j.medcle.2021.08.013. Epub 2022 Sep 1.

IF 3.9 Q2

Clinical Characteristics, Management, and In-Hospital Mortality in Patients with Heart Failure with Reduced Ejection Fraction According to Sex and the Presence of Type 2 Diabetes Mellitus.

Méndez-Bailón M, Lorenzo-Villalba N, Jiménez-García R, Hernández-Barrera V, de Miguel-Yanes JM, de Miguel-Diez J, **Muñoz-Rivas N**, Andrés E, Lopez-de-Andrés A. *J Clin Med*. 2022 Feb 16;11(4):1030. doi: 10.3390/jcm11041030.

IF 3.9 Q2

Increased Incidence of In-Hospital Ischemic Stroke During SARS-CoV-2 Outbreak: A Single-Center Study.

Sierra-Hidalgo F, Aragón Revilla E, Arranz García P, Martínez-Acebes E, Gómez-Moreno SM, **Muñoz-Rivas N**, Esquivel López A; Infanta Leonor Thrombosis Research Group. *Neurocrit Care*. 2022 Feb;36(1):208-215. doi: 10.1007/s12028-021-01286-1. Epub 2021 Jul 15

iF 3.5 Q2

Development of Neuropathic Post-COVID Pain Symptoms Is Not Associated with Serological Biomarkers at Hospital Admission in COVID-19 Survivors: A Secondary Analysis.

Fernández-de-Las-Peñas C, Herrero-Montes M, Ferrer-Pargada D, Izquierdo-Cuervo S, Palacios-Ceña D, Arendt-Nielsen L, Torres-Macho J, Parás-Bravo P. *Pain Med*. 2022 Dec 1;23(12):2092-2094. doi: 10.1093/pm/pnac086.

IF: 3.1 Q2

Serological biomarkers of COVID-19 severity at hospital admission are not related to long-term post-COVID pain symptoms in hospitalized COVID-19 survivors.

Fernández-de-Las-Peñas C, Ryan-Murua P, de-la-Llave-Rincón AI, Gómez-Mayordomo V, Arendt-Nielsen L, Torres-Macho J. *Pain*. 2022 Nov 1;163(11):2112-2117. doi: 10.1097/j.pain.0000000000002608.

IF: 7.4 Q1

Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants.

Fernández-de-Las-Peñas C, Cuadrado ML, Gómez-Mayordomo V, Torres-Macho J, Pellicer-Valero OJ, Martín-Guerrero JD, Arendt-Nielsen L. *Headache*. 2022 Oct;62(9):1148-1152. doi: 10.1111/head.14398.

IF: 5 Q1

Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial.

Muñoz-Rivas N, Aibar J, Gabara-Xancó C, Trueba-Vicente Á, Urbelz-Pérez A, Gómez-Del Olmo V, Demelo-Rodríguez P, Rivera-Gallego A, Bosch-Nicolau P, Perez-Pinar M, Rios-Prego M, Madridano-Cobo O, Ramos-Alonso L, Alonso-Carrillo J, Francisco-Albelsa I, Martí-Saez E, Maestre-Peiró A, Méndez-Bailón M, Hernández-Rivas JÁ, Torres-Macho J; PROTHROMCOVID Trial Investigators. *J Clin Med*. 2022 Sep 24;11(19):5632. doi: 10.3390/jcm11195632.

IF: 3.9 Q2

Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.

Franco-Moreno A, Acedo-Gutiérrez MS, Martín NL, Hernández-Blanco C, Rodríguez-Olleros C, Ibáñez-Estélez F, Suárez-Simón A, Balado-Rico M, Romero-Paternina AR, Alonso-Menchén D, Escolano-Fernández B, Piniella-Ruiz E, Alonso-Monge E, Notario-Leo H, Bibiano-Guillén C, Peña-Lillo G, Antigueira-Pérez A, Romero-Pareja R, Cabello-Clotet N, Estrada-Pérez V, Troya-García J, de Carranza-López M, Escobar-Rodríguez I, Vallejo-Maroto N, Torres-Macho J. *Trials*. 2022 Sep 15;23(1):784. doi: 10.1186/s13063-022-06722-x.

IF: 2.5 Q3

Differences in Long-COVID Symptoms between Vaccinated and Non-Vaccinated (BNT162b2 Vaccine) Hospitalized COVID-19 Survivors Infected with the Delta Variant.

Fernández-de-Las-Peñas C, Ortega-Santiago R, Fuensalida-Novo S, Martín-Guerrero JD, Pellicer-Valero OJ, Torres-Macho J. *Vaccines (Basel)*. 2022 Sep 6;10(9):1481. doi: 10.3390/vaccines10091481.

IF 7.8 Q1

The Effects of a Therapeutic Strategy Guided by Lung Ultrasound on 6-Month Outcomes in Patients with Heart Failure: Results from the EPICC Randomized Controlled Trial.

Torres-Macho J, Cerqueiro-González JM, Arévalo-Lorido JC, Llácer-Iborra P, Cepeda-Rodrigo JM, Cubo-Romano P, Casas-Rojo JM, Ruiz-Ortega R, Manzano-Espinosa L, Lorenzo-Villalba N, Méndez-Bailón M. *J Clin Med*. 2022 Aug 22;11(16):4930. doi: 10.3390/jcm11164930.

IF 3.9 Q2

Prevalence of Musculoskeletal Post-COVID Pain in Hospitalized COVID-19 Survivors Depending on Infection with the Historical, Alpha or Delta SARS-CoV-2 Variant.

Fernández-de-Las-Peñas C, Cancela-Cilleruelo I, Moro-López-Menchero P, Rodríguez-Jiménez J, Gómez-Mayordomo V, Torres-Macho J, Pellicer-Valero OJ, Martín-Guerrero JD, Hernández-Barrera V, Arendt-Nielsen L. *Biomedicines*. 2022 Aug 11;10(8):1951. doi: 10.3390/biomedicines10081951.

IF 4.7 Q2

Exploring the recovery curve for gastrointestinal symptoms from the acute COVID-19 phase to long-term post-COVID: The LONG-COVID-EXP-CM Multicenter Study.

Fernández-de-Las-Peñas C, Martín-Guerrero JD, Navarro-Pardo E, Torres-Macho J, Guijarro C, Pellicer-Valero OJ. *J Med Virol*. 2022 Jul;94(7):2925-2927. doi: 10.1002/jmv.27727. Epub 2022 Mar 26.

IF 12.7 Q1

Associated-Onset Symptoms and Post-COVID-19 Symptoms in Hospitalized COVID-19 Survivors Infected with Wuhan, Alpha or Delta SARS-CoV-2 Variant.

Fernández-de-Las-Peñas C, Cancela-Cilleruelo I, Rodríguez-Jiménez J, Gómez-Mayordomo V, Pellicer-Valero OJ, Martín-Guerrero JD, Hernández-Barrera V, Arendt-Nielsen L, Torres-Macho J. *Pathogens*. 2022 Jun 25;11(7):725. doi: 10.3390/pathogens11070725.

IF 3.7 Q2

Preexisting hypertension is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: a case-control study.

Fernández-de-Las-Peñas C, Torres-Macho J, Velasco-Arribas M, Plaza-Canteli S, Arias-Navalón JA, Hernández-Barrera V, Guijarro C. *J Hum Hypertens*. 2022 Jun;36(6):582-584. doi: 10.1038/s41371-022-00660-6. Epub 2022 Feb 16.

IF 2.3 Q3

Gastrointestinal symptoms at the acute COVID-19 phase are risk factors for developing gastrointestinal post-COVID symptoms: a multicenter study.

Fernández-de-Las-Peñas C, Martín-Guerrero J, Navarro-Pardo E, Torres-Macho J, Canto-Diez MG, Pellicer-Valero O. *Intern Emerg Med*. 2022 Mar;17(2):583-586. doi: 10.1007/s11739-021-02850-5. Epub 2021 Oct 12.

IF 4.6 Q2

Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care.

Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. *Liver Int*. 2022 Feb;42(2):309-319. doi: 10.1111/liv.15095. Epub 2021 Nov 17.

IF 6.7 Q1

Serological Biomarkers at Hospital Admission Are Not Related to Long-Term Post-COVID Fatigue and Dyspnea in COVID-19 Survivors.

Fernández-de-Las-Peñas C, Ryan-Murua P, Rodríguez-Jiménez J, Palacios-Ceña M, Arendt-Nielsen L, Torres-Macho J. *Respiration*. 2022;101(7):658-665. doi: 10.1159/000524042. Epub 2022 Apr 5.

IF 3.7 Q2

Effect of corticosteroids in patients with COVID-19 early stage pneumonia and risk of disease progression: An uncharted territory.

Franco-Moreno A, Acedo-Gutiérrez MS, Romero-Pareja R, Torres-Macho J. *Drug Discov Ther.* 2022;16(1):47-48. doi: 10.5582/ddt.2022.01008.

Fatigue and Dyspnoea as Main Persistent Post-COVID-19 Symptoms in Previously Hospitalized Patients: Related Functional Limitations and Disability.

Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Palacios-Ceña M, Rodríguez-Jiménez J, de-la-Llave-Rincón AI, Velasco-Arribas M, Fuensalida-Novo S, Ambite-Quesada S, Guijarro C, Cuadrado ML, Florencio LL, Arias-Navalón JA, Ortega-Santiago R, Elvira-Martínez CM, Molina-Trigueros LJ, Torres-Macho J, Sebastián-Viana T, Canto-Diez MG, Cigarán-Méndez M, Hernández-Barrera V, Arendt-Nielsen L. *Respiration.* 2022;101(2):132-141. doi: 10.1159/000518854. Epub 2021 Sep 21.

IF 3.7 Q2

Limitations of the Xpert-MTB/RIF® assay in the initial diagnosis of tuberculosis in the context of a rural hospital in Ethiopia.

Comeche B, Pérez-Butragueño M, Cuadros J, Tiziano G, Górgolas M, Ramos-Rincón JM.

Rev Esp Quimioter. 2022 Dec;35(6):559-562. doi: 10.37201/req/052.2022. Epub 2022 Sep 22.

PMID: 36129757

IF: 1.9 Q4

Impact of Xpert MTB/RIF in the Diagnosis of Childhood Tuberculosis in Rural Ethiopia.

Pérez-Butragueño M, Ramos-Rincón JM, Tesfamariam A, Comeche B, Mohammed N, Tiziano G, Endirays J, Biru D, Elala T, Edri A, Prieto L, Górgolas M. *J Trop Pediatr.* 2022 Jun 6;68(4):fmac055. doi: 10.1093/tropej/fmac055.

PMID: 35848941

IF: 0.62. Q3

Non-typhoidal Salmonella upper limb osteomyelitis and soft tissue abscess leading to a diagnosis of sickle cell anaemia.

Norman FF, Chamorro S, Tenorio MC, Monge B, García A, Comeche B, Pérez-Molina JA, López-Vélez R.

J Travel Med. 2022 Mar 21;29(2):taab152. doi: 10.1093/jtm/taab152.

PMID: 34581404

IF: 25.7 Q1

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.

Crespillo-Andújar C, Comeche B, Hamer DH, Arevalo-Rodriguez I, Alvarez-Díaz N, Zamora J, Pérez-Molina JA.

PLoS Negl Trop Dis. 2022 May 16;16(5):e0010386. doi:
10.1371/journal.pntd.0010386. eCollection 2022 May.
PMID: 35576215

IF: 1.08. Q1